Related Experiment Video

Updated: Aug 3, 2026

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

J P Kemp1, R J Dockhorn, G G Shapiro

  • 1Allergy and Asthma Medical Group and Research Center, San Diego, California, USA.

The Journal of Pediatrics
|September 17, 1998
PubMed

Insights

Montelukast significantly reduces exercise-induced bronchoconstriction (EIB) in children with asthma. This asthma medication provides approximately 59% protection against EIB at the end of the dosing interval.

Area of Science:

  • Pediatric Pulmonology
  • Pharmacology
  • Asthma Research

Background:

  • Exercise-induced bronchoconstriction (EIB) is a common condition in children with asthma.
  • Leukotriene receptor antagonists are a potential treatment for EIB.

Purpose of the Study:

  • To evaluate the efficacy of montelukast in attenuating EIB in children aged 6 to 14 years.
  • To assess the protective effect of montelukast at the end of the dosing interval.

Main Methods:

  • A double-blind, multicenter, 2-period crossover study was conducted.
  • Twenty-seven children with asthma underwent standardized exercise challenges after receiving montelukast or placebo.
  • Key endpoints included area under the curve of FEV1 fall, maximum FEV1 fall, and time to recovery.

Main Results:

  • Montelukast significantly reduced the area under the postexercise percent fall in FEV1 versus time curve (59% protection).
  • Montelukast also significantly reduced the maximum percent fall in FEV1 from pre-exercise baseline.
  • A trend towards shorter recovery time was observed with montelukast (P = .079).

Conclusions:

  • Montelukast effectively attenuates exercise-induced bronchoconstriction in children with asthma.
  • The protective effect of montelukast against EIB is evident at the end of the dosing interval.
Abstract

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Methodology for Sputum Induction and Laboratory Processing13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: